 |
市場調查報告書
商品編碼
1463113
格林巴利症候群市場,佔有率,規模,趨勢,行業分析報告:依治療藥物,給藥途徑,分銷管道,地區和細分市場預測2024-2032 年Guillain-Barre Syndrome Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032 |
||||||
價格
根據Polaris Market Research最新研究顯示，到2032年，全球格林巴利綜合症市場規模預計將達到9.6058億美元。該研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。
美國食品藥物管理局 (USFDA) 的藥品審批加速計畫在促進製藥業新產品審批大幅增加方面發揮著至關重要的作用。該倡議旨在加速創新藥物的開發和使用，特別是那些解決未滿足的醫療需求的藥物。透過簡化監管流程，美國食品藥物管理局為製藥公司將新療法推向市場創造了更有效的途徑，最終使患有各種疾病的患者受益。
新產品核准量迅速增加的一個值得注意的領域是格林-巴利綜合症 (GBS) 市場。GBS 是一種罕見的神經系統疾病，其特徵是免疫系統攻擊週邊神經，可導致肌肉無力和嚴重併發症。對加速藥物審批的重視刺激了 GBS 領域的研究和開發，從而推出了創新療法來應對這種疾病的獨特課題。
製藥公司正在增加對 GBS 研究的投資，利用監管機構簡化的流程來加快臨床試驗並更快地將潛在的治療方法推向市場。這不僅擴大了 GBS 患者的治療前景，也創造了更具競爭力的市場環境，鼓勵治療的進一步創新和進步。
FDA 批准的 GBS 藥物數量的增加證明了藥物批准加速計劃的積極影響，為醫療保健專業人員提供了管理和治療這種具有課題性的疾病的新工具。如果製藥業繼續採用這種加速審批系統，它可能會改變罕見疾病治療的格局，為患有格林-巴利綜合症等疾病的患者帶來希望並改善治療結果。
格林巴利綜合症市場報告亮點
由於免疫球蛋白輸注易於使用，預計未來幾年將出現最高成長。
由於靜脈免疫球蛋白治療的功效，母藥市場佔據最大市場佔有率
由於自體免疫病例的增加，預計醫院藥房部門將佔據更大的收入佔有率。
由於人口老化和該領域的技術創新，亞太地區將快速成長。
目錄
第一章簡介
第二章執行摘要
第三章研究方法論
第 4 章：格林巴利症候群全球市場洞察
- 格林巴利症候群市場 - 分銷通路快照
- 格林巴利症候群市場動態
- 驅動因素和機遇
- 格林-巴利症候群盛行率增加
- 吉蘭-巴利症候群的風險增加
- 限制因素和課題
- 缺乏治療意識可能會阻礙市場成長
- 驅動因素和機遇
- PESTEL 分析
- 格林巴利症候群市場分銷通路趨勢
- 價值鏈分析
- COVID-19 影響分析
第五章格林巴利症候群的全球市場（依治療領域）
- 主要發現
- 介紹
- 靜脈注射免疫球蛋白
- 血漿置換術
- 其他
第六章 吉蘭-巴利症候群的全球市場（依給藥途徑）
- 主要發現
- 介紹
- 口服
- 家長
第七章格林巴利症候群全球市場，依分銷管道
- 主要發現
- 介紹
- 醫院藥房
- 零售藥店
- 其他
第八章全球格林巴利症候群市場（依地區）
- 主要發現
- 介紹
- 格林巴利症候群市場評估，依地區，2019-2032
- 格林巴利症候群市場 - 北美
- 北美：格林巴利症候群市場，依治療領域，2019-2032
- 北美：格林巴利症候群市場，依通路劃分，2019-2032
- 北美：格林巴利症候群市場，依給藥途徑，2019-2032 年
- 格林巴利症候群市場—美國
- 格林巴利症候群市場－加拿大
- 格林巴利症候群市場—歐洲
- 歐洲：格林巴利症候群市場，依治療領域，2019-2032
- 歐洲：格林巴利症候群市場，依分銷管道劃分，2019-2032
- 歐洲：格林巴利症候群市場，依給藥途徑劃分，2019-2032 年
- 格林巴利症候群市場—英國
- 格林巴利症候群市場—法國
- 格林巴利症候群市場 - 德國
- 格林巴利症候群市場 - 義大利
- 格林巴利症候群市場－西班牙
- 格林巴利症候群市場－荷蘭
- 格林巴利症候群市場 - 俄羅斯
- 格林巴利症候群市場 - 亞太地區
- 亞太地區：格林巴利症候群市場，依治療領域，2019-2032
- 亞太地區：格林巴利症候群市場，依通路劃分，2019-2032 年
- 亞太地區：格林巴利症候群市場，依給藥途徑劃分，2019-2032 年
- 格林巴利症候群市場—中國
- 格林巴利症候群市場—印度
- 格林巴利症候群市場 – 馬來西亞
- 格林巴利症候群市場 - 日本
- 格林巴利症候群市場-印度尼西亞
- 格林巴利症候群市場 - 韓國
- 格林巴利症候群市場 - 中東和非洲
- 中東和非洲：格林巴利症候群市場，依治療領域，2019-2032
- 中東和非洲：格林巴利症候群市場，依通路劃分，2019-2032
- 中東和非洲：格林巴利症候群市場，依給藥途徑劃分，2019-2032 年
- 格林巴利症候群市場－沙烏地阿拉伯
- 格林巴利症候群市場 - 阿聯酋
- 格林巴利症候群市場—以色列
- 格林巴利症候群市場—南非
- 格林巴利症候群市場 - 拉丁美洲
- 拉丁美洲：格林巴利症候群市場，依治療領域，2019-2032
- 拉丁美洲：格林巴利綜合症市場，依分銷管道劃分，2019-2032 年
- 拉丁美洲：格林巴利症候群市場，依給藥途徑劃分，2019-2032 年
- 格林巴利症候群市場 - 墨西哥
- 格林巴利症候群市場－巴西
- 格林巴利症候群市場—阿根廷
第9章 競爭格局
- 擴張和收購分析
- 擴張
- 獲得
- 合作/協作/合約/展覽
第十章公司簡介
- Annexon Inc.
- Bayer AG
- Biotest AG
- Cellenkos Inc
- China Biologic Products Holdings Inc
- CSL Limited
- Grifols S A
- Kedrion Biopharma Inc
- Octapharma AG
- Takeda Pharmaceutical Company Limited
Product Code: PM4787
The global guillain-barre syndrome market size is expected to reach USD 960.58 million by 2032, according to a new study by Polaris Market Research. The report "Guillain-Barre Syndrome Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The accelerated drug approval initiative by the United States Food and Drug Administration (USFDA) has played a pivotal role in fostering a significant rise in new product approvals within the pharmaceutical industry. This initiative aims to expedite the development and availability of innovative drugs, particularly those addressing unmet medical needs. By streamlining regulatory processes, the USFDA has created a more efficient pathway for pharmaceutical companies to bring novel treatments to market, ultimately benefiting patients with various medical conditions.
One notable area experiencing a surge in new product approvals is the market for Guillain-Barre Syndrome (GBS). GBS is a rare neurological disorder characterized by the immune system attacking the peripheral nerves, leading to muscle weakness and potentially severe complications. The heightened focus on accelerating drug approvals has spurred research and development efforts in the GBS space, resulting in the introduction of innovative therapies designed to address the unique challenges posed by this disorder.
Pharmaceutical companies are increasingly investing in GBS research, leveraging the streamlined regulatory processes to expedite clinical trials and bring potential treatments to market faster. This has not only broadened the therapeutic landscape for GBS patients but has also created a more competitive market environment, encouraging further innovation and advancements in treatment options.
The positive impact of the accelerated drug approval initiative is evident in the growing number of FDA-approved drugs for GBS, providing healthcare professionals with additional tools to manage and treat this challenging condition. As the pharmaceutical industry continues to embrace these expedited pathways, it holds the potential to transform the landscape of rare disease treatment, offering hope and improved outcomes for patients with conditions like Guillain-Barre Syndrome.
Guillain-Barre Syndrome Market Report Highlights
Intravenous immunoglobulin segment is anticipated to witness the highest growth in the coming years due to its ease of application.
Parental segment accounted for the largest market share owing to its effectiveness in intravenous immunoglobulin therapy.
Hospital Pharmacies segment is projected to experience a larger revenue share due to the growing number of auto-immune cases.
Asia Pacific will grow rapidly, attributable to the presence of a geriatric population, and innovations in the sector
The global players include Annexon, Bayer, Biotest, Cellenkos, China Biologic Products Holdings, CSL Limited, & Grifols.
Polaris Market Research has segmented the Guillain-Barre syndrome market report based on therapeutics, route of administration, distribution channel and region:
Guillain-Barre Syndrome, Therapeutics Outlook (Revenue - USD Million, 2019 - 2032)
- Intravenous Immunoglobulin
- Plasma Exchange
- Others
Guillain-Barre Syndrome, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)
- Oral
- Parental
Guillain-Barre Syndrome, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Guillain-Barre Syndrome, Regional Outlook (Revenue - USD Million, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of APAC
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of MEA
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Guillain-Barre Syndrome Market Insights
- 4.1. Guillain-Barre Syndrome Market - Distribution Channel Snapshot
- 4.2. Guillain-Barre Syndrome Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising prevalence of Guillain-Barre syndrome cases
- 4.2.1.2. Increase in the risk of having Guillain-Barre syndrome
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Lower awareness about the treatment is likely to impede market growth
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Guillain-Barre Syndrome Market Distribution Channel Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Guillain-Barre Syndrome Market, by Therapeutic Area
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 5.3. Intravenous Immunoglobulin
- 5.3.1. Global Guillain-Barre Syndrome Market, by Intravenous Immunoglobulin, by Region, 2019-2032 (USD Million)
- 5.4. Plasma Exchange
- 5.4.1. Global Guillain-Barre Syndrome Market, by Plasma Exchange, by Region, 2019-2032 (USD Million)
- 5.5. Others
- 5.5.1. Global Guillain-Barre Syndrome Market, by Others, by Region, 2019-2032 (USD Million)
6. Global Guillain-Barre Syndrome Market, by Route of Administration
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 6.3. Oral
- 6.3.1. Global Guillain-Barre Syndrome Market, by Oral, by Region, 2019-2032 (USD Million)
- 6.4. Parental
- 6.4.1. Global Guillain-Barre Syndrome Market, by Parental, by Region, 2019-2032 (USD Million)
7. Global Guillain-Barre Syndrome Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 7.3. Hospital Pharmacies
- 7.3.1. Global Guillain-Barre Syndrome Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Million)
- 7.4. Retail Pharmacies
- 7.4.1. Global Guillain-Barre Syndrome Market, by Retail Pharmacies, By Region, 2019-2032 (USD Million)
- 7.5. Others
- 7.5.1. Global Guillain-Barre Syndrome Market, by Others, By Region, 2019-2032 (USD Million)
8. Global Guillain-Barre Syndrome Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Guillain-Barre Syndrome Market Assessment, By Geography, 2019-2032 (USD Million)
- 8.3. Guillain-Barre Syndrome Market - North America
- 8.3.1. North America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.3.2. North America: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.3. North America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.3.4. Guillain-Barre Syndrome Market - U.S.
- 8.3.4.1. U.S.: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.3.4.2. U.S.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.4.3. U.S.: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.3.5. Guillain-Barre Syndrome Market - Canada
- 8.3.5.1. Canada: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.3.5.2. Canada.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.5.3. Canada: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4. Guillain-Barre Syndrome Market - Europe
- 8.4.1. Europe: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.2. Europe.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.3. Europe: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.4. Guillain-Barre Syndrome Market - UK
- 8.4.4.1. UK: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.4.2. UK.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.4.3. UK: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.5. Guillain-Barre Syndrome Market - France
- 8.4.5.1. France: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.5.2. France.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.5.3. France: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.6. Guillain-Barre Syndrome Market - Germany
- 8.4.6.1. Germany: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.6.2. Germany.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.6.3. Germany: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.7. Guillain-Barre Syndrome Market - Italy
- 8.4.7.1. Italy: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.7.2. Italy.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.7.3. Italy: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.8. Guillain-Barre Syndrome Market - Spain
- 8.4.8.1. Spain: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.8.2. Spain.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.8.3. Spain: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.9. Guillain-Barre Syndrome Market - Netherlands
- 8.4.9.1. Netherlands: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.9.2. Netherlands.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.9.3. Netherlands: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.4.10. Guillain-Barre Syndrome Market - Russia
- 8.4.10.1. Russia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.4.10.2. Russia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.10.3. Russia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5. Guillain-Barre Syndrome Market - Asia Pacific
- 8.5.1. Asia Pacific: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.2. Asia Pacific.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.3. Asia Pacific: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5.4. Guillain-Barre Syndrome Market - China
- 8.5.4.1. China: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.4.2. China.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.4.3. China: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5.5. Guillain-Barre Syndrome Market - India
- 8.5.5.1. India: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.5.2. India.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.5.3. India: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5.6. Guillain-Barre Syndrome Market - Malaysia
- 8.5.6.1. Malaysia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.6.2. Malaysia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.6.3. Malaysia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5.7. Guillain-Barre Syndrome Market - Japan
- 8.5.7.1. Japan: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.7.2. Japan.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.7.3. Japan: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5.8. Guillain-Barre Syndrome Market - Indonesia
- 8.5.8.1. Indonesia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.8.2. Indonesia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.8.3. Indonesia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.5.9. Guillain-Barre Syndrome Market - South Korea
- 8.5.9.1. South Korea: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.5.9.2. South Korea.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.9.3. South Korea: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.6. Guillain-Barre Syndrome Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.6.2. Middle East & Africa.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.3. Middle East & Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.6.4. Guillain-Barre Syndrome Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.6.4.2. Saudi Arabia.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.4.3. Saudi Arabia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.6.5. Guillain-Barre Syndrome Market - UAE
- 8.6.5.1. UAE: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.6.5.2. UAE.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.5.3. UAE: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.6.6. Guillain-Barre Syndrome Market - Israel
- 8.6.6.1. Israel: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.6.6.2. Israel.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.6.3. Israel: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.6.7. Guillain-Barre Syndrome Market - South Africa
- 8.6.7.1. South Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.6.7.2. South Africa.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.7.3. South Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.7. Guillain-Barre Syndrome Market - Latin America
- 8.7.1. Latin America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.7.2. Latin America.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.3. Latin America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.7.4. Guillain-Barre Syndrome Market - Mexico
- 8.7.4.1. Mexico: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.7.4.2. Mexico.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.4.3. Mexico: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.7.5. Guillain-Barre Syndrome Market - Brazil
- 8.7.5.1. Brazil: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.7.5.2. Brazil.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.5.3. Brazil: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- 8.7.6. Guillain-Barre Syndrome Market - Argentina
- 8.7.6.1. Argentina: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- 8.7.6.2. Argentina.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.6.3. Argentina: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Annexon Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Bayer AG
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Biotest AG
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Cellenkos Inc
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. China Biologic Products Holdings Inc
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. CSL Limited
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Grifols S A
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Kedrion Biopharma Inc
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Octapharma AG
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Takeda Pharmaceutical Company Limited
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
List of Tables
- Table 1 Global Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 2 Global Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 3 Global Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 4 Guillain-Barre Syndrome Market Assessment, By Geography, 2019-2032 (USD Million)
- Table 5 North America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 6 North America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 7 North America: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 8 U.S.: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 9 U.S.: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 10 U.S.: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 11 Canada: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 12 Canada: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 13 Canada: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 14 Europe: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 15 Europe: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 16 Europe: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 17 UK: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 18 UK: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 19 UK: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 20 France: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 21 France: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 22 France: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 23 Germany: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 24 Germany: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 25 Germany: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 26 Italy: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 27 Italy: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 28 Italy: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 29 Spain: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 30 Spain: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 31 Spain: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 32 Netherlands: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 33 Netherlands: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 34 Netherlands: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 35 Russia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 36 Russia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 37 Russia: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 38 Asia Pacific: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 39 Asia Pacific: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 40 Asia Pacific: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 41 China: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 42 China: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 43 China: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 44 India: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 45 India: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 46 India: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 47 Malaysia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 48 Malaysia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 49 Malaysia: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 50 Japan: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 51 Japan: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 52 Japan: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 53 Indonesia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 54 Indonesia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 55 Indonesia: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 56 South Korea: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 57 South Korea: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 58 South Korea: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 59 Middle East & Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 60 Middle East & Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 61 Middle East & Africa: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 62 Saudi Arabia: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 63 Saudi Arabia: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 64 Saudi Arabia: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 65 UAE: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 66 UAE: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 67 UAE: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 68 Israel: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 69 Israel: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 70 Israel: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 71 South Africa: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 72 South Africa: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 73 South Africa: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 74 Latin America: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 75 Latin America: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 76 Latin America: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 77 Mexico: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 78 Mexico: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 79 Mexico: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 80 Brazil: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 81 Brazil: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 82 Brazil: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
- Table 83 Argentina: Guillain-Barre Syndrome Market, by Therapeutic Area, 2019-2032 (USD Million)
- Table 84 Argentina: Guillain-Barre Syndrome Market, by Route of Administration, 2019-2032 (USD Million)
- Table 85 Argentina: Guillain-Barre Syndrome Market, by Distribution Channel, 2019-2032 (USD Million)
List of Figures
- Figure 1. Global Guillain-Barre Syndrome Market, 2019-2032 (USD Million)
- Figure 2. Integrated Ecosystem
- Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
- Figure 4. Market by Geography
- Figure 5. Porter's Five Forces
- Figure 6. Market by Route of Administration
- Figure 7. Global Guillain-Barre Syndrome Market, by Route of Administration, 2022 & 2032 (USD Million)
- Figure 8. Market by Therapeutic Area
- Figure 9. Global Guillain-Barre Syndrome Market, by Therapeutic Area, 2022 & 2032 (USD Million)
- Figure 10. Market by Distribution Channel
- Figure 11. Global Guillain-Barre Syndrome Market, by Distribution Channel, 2022 & 2032 (USD Million)
- Figure 12. Guillain-Barre Syndrome Market Assessment, By Geography, 2019-2032 (USD Million)
- Figure 13. Strategic Analysis - Guillain-Barre Syndrome Market
